Norge - norsk - Statens legemiddelverk

linde sverige ab - dinitrogenoksid - medisinsk gass, flytende - 100 %

Norge - norsk - Statens legemiddelverk

g. pohl-boskamp gmbh & co. - glyseryltrinitrat - sublingvalspray - 0.4 mg/ dose

Norge - norsk - Statens legemiddelverk

orifarm generics a/s - ursodeoksykolsyre - kapsel, hard - 250 mg

Norge - norsk - Statens legemiddelverk

orion corporation - espoo - ursodeoksykolsyre - kapsel, hard - 250 mg

Norge - norsk - Statens legemiddelverk

abacus medicine a/s - entekavirmonohydrat - tablett, filmdrasjert - 0.5 mg

Norge - norsk - Statens legemiddelverk

abacus medicine a/s - entekavirmonohydrat - tablett, filmdrasjert - 1 mg

Norge - norsk - Statens legemiddelverk

air liquide santé international - nitrogenmonoksid - medisinsk gass, komprimert - 800 ppm (mol pr. mol)

Den europeiske union - norsk - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioødemer, arvelig - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Den europeiske union - norsk - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunsuppressive - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, alene eller i kombinasjon med metotreksat (mtx), er indisert for behandling av aktiv psoriasisartritt hos voksne pasienter når responsen på tidligere sykdom endre anti revmatiske legemiddel (dmard) terapi har vært mangelfull. axial spondyloarthritis (axspa)bekhterevs sykdom (as, røntgenologisk aksial spondyloarthritis)cosentyx er angitt for behandling av aktiv bekhterevs sykdom hos voksne som har svart ikke til konvensjonell terapi. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.